How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

During the previous two years, 321 institutional investors and hedge funds held shares of Recursion Pharmaceuticals. The most heavily invested institutionals were Vanguard Group Inc. ($193.00M), ARK ...

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter. Learn about the media sentiment score. Each ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Abstract: A method is discussed for estimating the state of a linear dynamic system using noisy observations, when the input to the dynamic system and the observation errors are completely unknown ...

Abstract: Approximate computing, frequently used in error tolerant applications, aims to achieve higher circuit performances by allowing the possibility of inaccurate ...